| Filed On | Filing |
|---|---|
| 23 Oct 2020 |
8-K/A: Submission of Matters to a Vote of Security Holders
As previously reported in the Original Form 8-K, in a non-binding advisory vote on the frequency of future Say-on-Pay votes held at the 2020 Annual Meeting, 18,391,807 shares voted for one year, 368,753 shares voted for two years, 124,37... |
| 23 Mar 2011 |
8-K/A: Financial Statements and Exhibits
Protalix BioTherapeutics, Inc. — Offering of 4,000,000 Shares of Common Stock |
| 15 Oct 2009 |
8-K/A: Other Events
Protalix BioTherapeutics Announces Positive Top-line Results from its Phase III Clinical Trial of UPLYSO™ for the Treatment of Gaucher Disease |
| 20 Sep 2007 |
8-K/A: Financial Statements and Exhibits
Portions of this exhibit have been omitted pursuant to a request for confidential treatment. The omitted portions, marked by [***], have been separately filed with the Securities and Exchange Commission. |
| 22 Feb 2007 |
8-K/A: Changes in Registrant's Certifying Accountant
We have read Item 4.01 of Form 8-K dated February 16, 2007 of Orthodontix, Inc. and are in agreement with the statements regarding Sherb & Co., LLP contained therein. |
| 18 May 2005 |
8-K/A: Changes in Registrant's Certifying Accountant
On February 11, 2005, Orthodontix, Inc. (the "Company") engaged Salberg & Company, P.A. as the Company's principal accountant to audit the Company's financial statements. |
| 24 Nov 2004 |
8-K/A: Changes in Registrant's Certifying Accountant
We have read the statements made by Orthodontix, Inc. (copy attached), which we understand will be filed with the Commission, pursuant to Item 4.01 of Form 8-K, as part of Orthodontix’s Form 8-K/A report dated November 12, 2004. We agree... |
| 30 Jun 1998 |
8-K/A: Financial Statements and Exhibits
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 |
Loading...